AT294504T

Methods and compositions for treatment of cell proliferative disorders

Abstract

The invention relates to methods and compositions, and compositions at least comprises a endothelin antagonist, the is preferably designed with is β -1,4-N- acetyl glucosamine (p-GlcNAc) polysaccharide matrix combined to the other cancers and hyperphasia diseases' compositions. The endothelin antagonists can be peptide And Huo non-peptide compounds, the p-GlcNA in the invention comprises a macromolecular weight polymer, wherein monosaccharide component is β -1,4 are connected, and are monosaccharide and) respectively comprises a protein, basically and a single amino acid, does not contain the organic and inorganic discharging. The compositions and methods of the invention can be used for inhibiting the growth of the tumours and lump cells, and/or a restraining body lump the transfusion.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

80 members in 17 offices

This recordMember, by publication datePriority claim7 more offices are in the list below

Priority claims2

Priority claims
DocumentOfficeKindDate
21828898United States of AmericaA
9930575United States of AmericaW

Members80

Family members, oldest first
DocumentOfficeKind
IL111825D0IsraelD0
CA2177823A1CanadaA1
CA2372026A1CanadaA1
CA2604073A1CanadaA1
WO9515343A1World Intellectual Property Organization (WIPO)A1
AU1296995AAustraliaA
EP0731812A1European Patent Office (EPO)A1
WO9639122A1World Intellectual Property Organization (WIPO)A1
AU5917896AAustraliaA
CN1142833AChinaA
US5622834AUnited States of AmericaA
US5623064AUnited States of AmericaA
US5624679AUnited States of AmericaA
US5635493AUnited States of AmericaA
JPH09506126AJapanA
EP0731812A4European Patent Office (EPO)A4
US5686115AUnited States of AmericaA
NZ277662ANew ZealandA
AU695850B2AustraliaB2
US5846952AUnited States of AmericaA
US5858350AUnited States of AmericaA
US6063911AUnited States of AmericaA
CA2356087A1CanadaA1
WO0036918A1World Intellectual Property Organization (WIPO)A1
AU2591900AAustraliaA
WO0036918A9World Intellectual Property Organization (WIPO)A9
NO20013071D0NorwayD0
NO20013071LNorwayL
EP1139752A1European Patent Office (EPO)A1
TW458987BTaiwan Province of ChinaB
US2001055807A1United States of AmericaA1
CN1335749AChinaA
IL143700D0IsraelD0
CA2177823CCanadaC
US2002091101A1United States of AmericaA1
US2002098579A1United States of AmericaA1
US2002106792A1United States of AmericaA1
HK1043507A1Hong Kong, ChinaA1
EP1139752A4European Patent Office (EPO)A4
JP2003522732AJapanA
US6599720B2United States of AmericaB2
US6610668B2United States of AmericaB2
US6630459B2United States of AmericaB2
US2003212040A1United States of AmericaA1
US6649599B2United States of AmericaB2
NZ512586ANew ZealandA
US6686342B2United States of AmericaB2
EP0731812B1European Patent Office (EPO)B1
AT263785TAustriaT
ATE263785T1AustriaT1
US2004087015A1United States of AmericaA1
DE69433692D1GermanyD1
US6743783B1United States of AmericaB1
JP2004211101AJapanA
DK0731812T3DenmarkT3
PT731812EPortugalE
EP1452546A2European Patent Office (EPO)A2
EP1452546A3European Patent Office (EPO)A3
ES2219659T3SpainT3
US2005004072A1United States of AmericaA1
US6864245B2United States of AmericaB2
AU780248B2AustraliaB2
DE69433692T2GermanyT2
EP1139752B1European Patent Office (EPO)B1
AT294504TThis recordAustriaT
ATE294504T1AustriaT1
DE69925156D1GermanyD1
ES2242448T3SpainT3
DE69925156T2GermanyT2
IL143700AIsraelA
US2007105815A1United States of AmericaA1
JP3993633B2JapanB2
CA2356087CCanadaC
JP2009079223AJapanA
CN100488512CChinaC
US2009247738A1United States of AmericaA1
HK1043507BHong Kong, ChinaB
CN1142833BChinaB
NO330033B1NorwayB1
JP4795539B2JapanB2